Back
Top 39%
17.5%
Top 13%
11.7%
Top 19%
7.7%
Top 0.9%
5.9%
Top 2%
5.0%
Top 5%
4.1%
Top 12%
3.8%
Top 2%
3.1%
Top 5%
1.9%
Top 9%
1.9%
Top 10%
1.9%
Top 4%
1.5%
Top 0.8%
1.5%
Top 47%
1.3%
Top 7%
0.9%
Top 5%
0.7%
Top 30%
0.7%
Top 26%
0.7%
Top 6%
0.7%
Top 34%
0.7%
Top 11%
0.7%
Top 8%
0.7%
The Impact of MFN on Oncology and Hematology Treatments
2026-02-20
health economics
Title + abstract only
View on medRxiv
Show abstract
BackgroundThe Most Favored Nation (MFN) policy is a mechanism that incorporates foreign prices to determine the maximum allowable net price for any branded drug within US government-funded healthcare. Two proposed rules, the Global Benchmark for Efficient Drug Pricing ("GLOBE") (90 Fed. Reg. 60,244) for Medicare Part B and the Guarding US Medicare Against Rising Drug Costs ("GUARD") (90 Fed. Reg. 60,338) for Medicare Part D, invoke the Center for Medicare and Medicaid Innovation Centers payment ...
Predicted journal destinations
1
PLOS ONE
1737 training papers
2
Scientific Reports
701 training papers
3
BMJ Open
553 training papers
4
Proceedings of the National Academy of Sciences
100 training papers
5
JAMA Network Open
125 training papers
6
BMC Medicine
155 training papers
7
eLife
262 training papers
8
BMC Health Services Research
43 training papers
9
PLOS Medicine
95 training papers
10
Journal of Medical Internet Research
81 training papers
11
npj Digital Medicine
85 training papers
12
BMC Cancer
21 training papers
13
International Journal of Cancer
18 training papers
14
Nature Communications
483 training papers
15
Genetics in Medicine
57 training papers
16
British Journal of Cancer
22 training papers
17
BMC Public Health
148 training papers
18
Clinical Infectious Diseases
219 training papers
19
eClinicalMedicine
55 training papers
20
PLOS Global Public Health
287 training papers
21
Vaccine
140 training papers
22
Cancers
57 training papers